(R)-4-benzyl-3-methyl-1,3-oxazolidin-2-one | 128275-88-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑烷类
• 英文名称: (R)-4-benzyl-3-methyl-1,3-oxazolidin-2-one
• 英文别名: (R)-3-methyl-4-benzyloxazolidin-2-one；(4R)-4-benzyl-3-methyl-1,3-oxazolidin-2-one
• CAS: 128275-88-7
• 化学式: C₁₁H₁₃NO₂
• 分子量: 191.23
• InChiKey: CAXLCRGKHDWKRY-SNVBAGLBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (R)-4-benzyl-3-methyl-1,3-oxazolidin-2-one 在 硝酸 作用下， 以 二氯甲烷 为溶剂， 生成 (R)-3-Methyl-4-(4-nitro-benzyl)-oxazolidin-2-one
  参考文献：
  名称：

  Design, synthesis, and evaluation of 4-(4′-aminobenzyl)-2-oxazolidinones as novel inhibitors of the cytochrome P-450 enzyme aromatase

  摘要：

  The synthesis of a series of N-alkylated 4-(4'aminobenzyl)-2-oxazolidinones is described using a synthetically useful scheme which avoids the use of phosgene-since the derivatization is undertaken with the oxazolidin-2-one ring intact. The compounds were tested for human placental aromatase (AR) inhibition in vitro, using [1beta, 2beta-H-3]androstenedione as substrate for the AR enzyme. The compounds were found, in general, to be more potent than the standard compound, aminoglutethimide (AG), and as such proved to be good lead compounds in the search for more specific AR inhibitors. (C) 2002 Elsevier Science (USA). All rights reserved.

  DOI：

  10.1016/s0045-2068(02)00017-2
• 作为产物：
  描述：

  (R)-4-苄基-2-噁唑烷酮 、 alkaline earth salt of/the/ methylsulfuric acid 在 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 (R)-4-benzyl-3-methyl-1,3-oxazolidin-2-one
  参考文献：
  名称：

  Design, synthesis, and evaluation of 4-(4′-aminobenzyl)-2-oxazolidinones as novel inhibitors of the cytochrome P-450 enzyme aromatase

  摘要：

  The synthesis of a series of N-alkylated 4-(4'aminobenzyl)-2-oxazolidinones is described using a synthetically useful scheme which avoids the use of phosgene-since the derivatization is undertaken with the oxazolidin-2-one ring intact. The compounds were tested for human placental aromatase (AR) inhibition in vitro, using [1beta, 2beta-H-3]androstenedione as substrate for the AR enzyme. The compounds were found, in general, to be more potent than the standard compound, aminoglutethimide (AG), and as such proved to be good lead compounds in the search for more specific AR inhibitors. (C) 2002 Elsevier Science (USA). All rights reserved.

  DOI：

  10.1016/s0045-2068(02)00017-2

文献信息

• [EN] FLUORINATED ARYL AMIDE COMPOUNDS<br/>[FR] COMPOSÉS FLUORÉS D'ARYLE ET D'AMIDE
  申请人：CASCADE THERAPEUTICS INC

  公开号：WO2009079763A1

  公开（公告）日：2009-07-02

  A compound of Formula I : The compound can be used in the treatment of epilepsy, neuropathic pain, acute and chronic inflammatory pain, migraine, tardive dyskinesia and other related CNS disorders.

  化合物I的公式为：该化合物可用于治疗癫痫、神经病性疼痛、急性和慢性炎症性疼痛、偏头痛、迟发性运动障碍和其他相关的中枢神经系统疾病。
• PROCESS FOR THE PREPARATION OF KINASE INHIBITORS AND INTERMEDIATES THEREOF
  申请人：Aerie Pharmaceuticals, Inc.

  公开号：US20170204065A1

  公开（公告）日：2017-07-20

  Described are processes for the synthesis of certain compounds, useful for treating diseases, e.g. eye disease, such as glaucoma and ocular hypertension, in a subject.

  本文描述了一些合成特定化合物的过程，这些化合物可用于治疗一些疾病，例如眼病，如青光眼和眼压增高，适用于治疗患者。
• FLUORO- AND TRIFLUOROALKYL-CONTAINING HETEROCYCLIC SULFONAMIDE INHIBITORS OF BETA AMYLOID PRODUCTION AND DERIVATIVES THEREOF
  申请人：Kreft Anthony Frank

  公开号：US20090227667A1

  公开（公告）日：2009-09-10

  Compounds of Formula (I), are provided where T is CHO, COR 8 , or C(OH)R 1 R 2 ; R 1 and R 2 are hydrogen, optionally substituted lower alkyl, CF 3 , optionally substituted alkenyl, or optionally substituted alkynyl; R 3 is hydrogen or optionally substituted lower alkyl; R 4 is (CF 3 ) n alkyl, (CF 3 ) n (substitutedalkyl), (CF 3 ) n alkylphenyl, (CF 3 ) n alkyl(substitutedphenyl), or (F) n cycloalkyl; n=1-3; R 5 is hydrogen, halogen, CF 3 , diene fused to Y when Y=C, or substituted diene fused to Y when Y=C; W, Y and Z are C, CR 6 or N where at least one of W, Y or Z are C; R 6 is hydrogen, halogen, or optionally substituted lower alkyl; X is O, S, SO 2 , or NR 7 ; R 7 is hydrogen, optionally substituted lower alkyl, optionally substituted benzyl, or optionally substituted phenyl; and R 8 is lower alkyl, CF 3 , or optionally substituted phenyl. Methods of preparing and using these compounds for inhibiting beta amyloid production and for treatment of Alzheimer's Disease and Down's syndrome are also described.

  提供了化学式（I）的化合物，其中T为CHO，COR8或C（OH）R1R2; R1和R2为氢，可选取代的低级烷基，CF3，可选取代的烯基或可选取代的炔基; R3为氢或可选取代的低级烷基; R4为（ ）n烷基，（ ）n（取代烷基），（ ）n烷基苯基，（ ）n烷基（取代苯基）或（F）n环烷基; n = 1-3; R5为氢，卤素， ，与Y融合的二烯或与Y融合的取代二烯，当Y = C时; W，Y和Z为C，CR6或N，其中至少有一个为C; R6为氢，卤素或可选取代的低级烷基; X为O，S，SO2或NR7; R7为氢，可选取代的低级烷基，可选取代的苄基或可选取代的苯基; R8为低级烷基， 或可选取代的苯基。还描述了制备和使用这些化合物来抑制β淀粉样蛋白生成以及治疗阿尔茨海默病和唐氏综合症的方法。
• NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE
  申请人：Ishibuchi Seigo

  公开号：US20110263571A1

  公开（公告）日：2011-10-27

  Provided are a novel low-molecular-weight compound that suppresses production of induction type MMPs, particularly MMP-9, rather than production of hemostatic type MMP-2, as well as a prophylactic/therapeutic drug for autoimmune diseases or osteoarthritis. An amide derivative represented by the following formula (I) wherein each symbol is as defined in the specification, a pharmacologically acceptable salt thereof, or a hydrate or solvate thereof.

  提供了一种新型低分子量化合物，可抑制诱导型MMPs，特别是MMP-9的产生，而不是止血型MMP-2的产生，以及用于自身免疫性疾病或骨关节炎的预防/治疗药物。该化合物为以下式子（I）所表示的酰胺衍生物，其中每个符号如规范中所定义，其药理学上可接受的盐，或其水合物或溶剂化物。
• Bile acid analogs as FXR/TGR5 agonists and methods of use thereof
  申请人：Enanta Pharmaceuticals, Inc.

  公开号：US10266560B2

  公开（公告）日：2019-04-23

  The present invention relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof, where R1, R2, R3, R4, R5, R6, R7, R8 and m are as defined herein, pharmaceutical compositions comprising these compounds and methods of use of these compounds for treating a TGR5 mediated disease or condition.

  本发明涉及式（I）化合物、 及其药学上可接受的盐，其中 R1、R2、R3、R4、R5、R6、R7、R8 和 m 如本文所定义；包含这些化合物的药物组合物；以及使用这些化合物治疗 TGR5 介导的疾病或病症的方法。